Innovative Therapeutics Forge Therapeutics specializes in developing novel metalloprotein inhibitors by targeting the metal ion in enzyme active sites, positioning them at the forefront of innovative drug discovery in the biotechnology sector.

Strategic Partnerships The company's collaborations with Roche, Basilea Pharmaceutica, and strategic alliances with Evotec AG indicate a strong network for joint development of advanced antibiotics, presenting opportunities for vendors and service providers in biotech R&D support.

Recent Merger Expansion The merger with Blacksmith Medicines expands Forge’s capabilities into immuno-oncology, opening potential cross-sector collaboration opportunities with firms operating in cancer immunotherapy and related fields.

Funding & Recognition Multiple government awards including CARB-X highlight the company’s recognition and support in antibiotic development, suggesting a focus area for suppliers providing research funding, grants, or specialized biotech tools.

Growth & Opportunities With a small team and revenue under one million dollars, Forge offers a promising opportunity for early-stage biotech suppliers, service providers, and investors looking to partner with a pharma-focused biotech innovator in the infectious disease and metalloprotein space.